CPRX - Catalyst Pharma secures new U.S. patent covering Firdapse

The USPTO has issued a new patent for Catalyst Pharmaceuticals' (CPRX) Firdapse (amifampridine) Tablets 10mg, U.S. Patent No. 11,060,128, Methods of Administering 3,4-diaminopyridine. “This patent is directed to innovative methods of administering amifampridine to slow metabolizers of amifampridine for the treatment of LEMS,” commented Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer.The company will submit a request to the FDA that this patent be listed in FDA’s Orange Book.Lambert–Eaton myasthenic syndrome ((LEMS)) is a rare autoimmune disorder characterized by muscle weakness of the limbs.

For further details see:

Catalyst Pharma secures new U.S. patent covering Firdapse